Resistance patterns and trends of extensively drug-resistant tuberculosis: 5-year experience

Yıl 2013, Cilt: 3 Sayı: 04, 169 - 175, 01.12.2013

Amresh Kumar Singh Anand Kumar Maurya Manoj Kumar Surya Kant Ram Awadh Singh Kushwaha Vijaya Lakshmi Nag Tapan N Dhole

https://doi.org/10.5799/ahinjs.02.2013.04.0103

Cited By: 1

Öz

Objective: Extensively drug-resistant tuberculosis (XDR-TB) strains were emerged when multidrug-resistant TB (MDR-TB) was inadequately treated. Inadequate treatment of MDR-TB cases may result in additional resistance especially non-XDR-TB and then XDR-TB. The aim of this study was to know the prevalence, resistance patterns and trends of the XDR-TB strains among the MDR-TB at a tertiary care hospital in Lucknow, India Methods: A total of 430 Mycobacterium isolates were underwent NAP test and TB MPT64 Ag test for the identification of Mycobacterium tuberculosis complex (MTBC). Drug-susceptibility test (DST) was performed over MTBC for the first line drugs by 1% proportion method (Bactec) and for the second-line drugs by 1% proportion method (Lowenstein-Jensen media). The XDR-TB status was further confirmed by line probe assay (GenoType® MTBDRsl assay). Results: Among the 430 isolates of mycobacterium, 365 (84.9%) were MTBC and 139 (38.1%) were MDR-TB respectively. Further 97 MDR-TB from "highly suspected drug resistant-TB (DR-TB)" cases among MDR-TB were tested with second line drugs in which 15 (15.5%) XDR-TB and 82 (84.5%) were non-XDR-TB. Regarding XDR-TB status, using the 1% proportion method a 100% agreement was seen with the GenoType® MTBDRsl assay. Resistance patterns of XDR-TB were as; 10/15 (66.7%) as isoniazid + rifampicin + ciprofloxacin + amikacin resistance and 5/15 (33.3%) as isoniazid + rifampicin + ciprofloxacin + amikacin + kanamycin resistance. Conclusion: The prevalence of XDR-TB was 15.5% among MDR-TB. Hence laboratory testing of "highly suspected drug resistant-TB" isolates should be done for both first and second line drugs simultaneously especially in developing countries.

Anahtar Kelimeler

Mycobacterium tuberculosis, extensively drug-resistant tuberculosis, multi drug-resistance tuberculosis, India

Resistance patterns and trends of extensively drug-resistant tuberculosis: 5-year experience

Öz

Amaç: Genişlemiş drug-rezistan tüberküloz (XDR-TB) suşları multi-drug rezistan tüberküloz (MDR-TB) suşlarının uygunsuz tedavisiyle önem kazandı. Multi-drug rezistan tüberküloz (MDR-TB) suşları ile infekte olguların uygunsuz tedavisi özellikle XDR-TB dışı ve XDR-TB’a yol açabilir. Bu çalışmada Hindistan’ın Luckdown şehrindeki bir üçüncü basamak hastanesinde multidrug-rezistan tüberküloz suşları arasında genişlemiş drug-rezistans paterni ve trendinin araştırılması amaçlandı. Yöntemler: Çalışmada Mycobacteruim tuberculosis complex (MTBC) identifikasyonu için 430 mikobakteri suşu NAP testi ve TB MPT64 Ag testine tabi tutuldu. İlaç duyarlılıklarının belirlenmesinde ilk sıra ilaçlar için % 1 proporsiyon metodu (Bactec) XDR-TB durumu GenoType® MTBDRslassay ile doğrulandı.Bulgular: Toplam 430 mikobakteriden 365’i (% 84,9) MTBC ve 139’u (% 38,1) MDR-TB olarak tanımlandı. Yüksek oranda drug-rezistan-TB (DR-TB) olarak düşünülen 97 MDR-TB suşu ikinci sıra antitüberküloz ilaçlara duyarlılık açısındn test edildiğinde suşlardan 15’i (% 15,5) XDR-TB ve 82’si (% 84,5) ise XDR-TB dışı suşlar idi. XDR-TB suşlarının tamamı %1 proporsiyon testi kullanılarak GenoType® MTBDRsl assay ile doğrulandı. Toplam 15 XDR-TB suşundan 10’u (% 66,7) izoniazid + rifampisin + siprofloksazin + amikasin ve 5’i (% 33,3%) izoniazid + rifampisin + siprofloksazin + amikasin + kanamisin’e dirençli olarak değerlendirildi.Sonuç: Bu çalışmada MDR-TB suşları arasında XDR-TB prevalansı % 15,5 olarak bulunmuştur. Bu yüzden özellikle gelişmekte olan ülkelerde yüksek şüpheli drug-rezistan TB durumunda suşların ilk ve ikinci sıra antitüberküloz ilaçlara duyarlılığının birlikte araştırılması gerektiğini düşünüyoruz

Anahtar Kelimeler

Mycobacterium tuberculosis, genişlemiş drug-rezistan tüberküloz, multidrug-rezistan tüberküloz, Hindistan

Kaynakça

• 1. World Health Organization. Global Tuberculosis Control-Surveillance, Planning, Financing. World Health Organization Report, Geneva, Switzerland: WHO, 2008. http:// www.who. int/ tb/ publications/ global report/ 2008/en/index.html [Last Accessed on 5 August 2012].
• 2. A Directorate of Health Services, Ministry of Health & family welfare, www.tbcindia.org, 2009. [Last Accessed on 2 April 2012].
• 3. Steinbrook R. Tuberculosis and HIV in India. N Engl J Med 2007; 356:1198-1199.
• 4. Nathanson E, Nunn P, Uplekar M et al. MDR tuberculosiscritical steps for prevention and control. N Engl J Med 2010;363:1050-1058.
• 5. Zignol M, Hosseini MS, Wright A, et al. Global incidence of multidrug-resistant tuberculosis. J Infect Dis 2006; 194:479- 485.
• 6. Maurya AK, Kant S, Kushwaha RAS, Nag VL. Extensively drug resistance Tuberculosis - New generation of drug resistance. J Bioscience and Technology 2011;2:312-317.
• 7. Kant S, Maurya AK, Kushwaha RA, Nag VL, Prasad R. Multidrug resistant tuberculosis: an iatrogenic problem. Biosci Trends 2010;4:48-55.
• 8. Kubica GP, Gontijo-Filho PP, Kim T. Preservation of mycobacteria st -70 degrees C: persistence of key differential features. J Clin Microbiol 1977;6:149-153.
• 9. Siddiqui SH. BACTEC 460 TB system. Product and procedure manual. Becton Dickinson Microbiology System. Sparks, MD. 1996.
• 10. Maurya AK, Nag VL, Kant S, et al. Evaluation of an immunochromatographic test for discrimination between Mycobacterium tuberculosis complex & non tuberculous mycobacteria in clinical isolates from extra-pulmonary tuberculosis. Indian J Med Res 2012; 135:901-906.
• 11. Ismail NA, Baba K, Pombo D, Hoosen AA. Use of an immunochromatographic kit for the rapid detection of Mycobacterium tuberculosis from broth cultures. Int J Tuberc Lung Dis 2009;13:1045-1047.
• 12. Canetti G, Froman S, Grosset J, et al. Mycobacteria: Laboratory Methods for Testing Drug Sensitivity and Resistance. Bull World Health Organ 1963; 29:565-578.
• 13. World Health Organization. Guidelines for drug susceptibility testing for second line anti-tuberculosis drugs for DOTSPlus: WHO/CDS/TB/2001.288, Geneva, Switzerland (accessed August 28 2012).
• 14. Mondal R, Jain A. Extensively drug-resistant Mycobacterium tuberculosis, India. Emerg Infect Dis 2007;13:1429-1431.
• 15. Hillemann D, Rusch-Gerdes S, Richter E. Feasibility of the GenoType® MTBDRsl assay for fluoroquinolone, amikacincapreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2009; 47:1767-1772.
• 16. World Health Organization. Joint United Nations Programme on HIV/AIDS (UNAIDS)-WHO. Revised recommendations for the selection and use of HIV antibody tests. Wkly Epidemiol Rec 1997; 72: 81–87.
• 17. Sharma SK, George N, Kadhiravan T et al. Prevalence of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: a retrospective hospitalbased study. Indian J Med Res 2009;130:392-395.
• 18. Datta BS, Hassan G, Kadri SM, et al. Multidrug-resistant and extensively drug-resistant tuberculosis in Kashmir, India. J Infect Dev Ctries 2010; 4:19-23.
• 19. World Health Organization. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015. WHO progress report 201.WHO/HTM/TB/2011.3. Geneva: World Health Organization. 2011.
• 20. Shah NS, Richardson J, Moodley P, et al. Increasing drug resistance in extensively drug-resistant tuberculosis, South Africa. Emerg Infect Dis 2011; 17:510-513.
• 21. Deivanayagam CN, Rajasekaran S, Venkatesan R et al. Prevalence of acquired MDR-TB and HIV co-infection. Indian J Chest Dis Allied Sci 2002; 44:237-242.
• 22. Singh S, Sankar MM, Gopinath K. High rate of extensively drug-resistant tuberculosis in Indian AIDS patients. AIDS 2007;21:2345-2347.
• 23. Gandhi NR, Shah NS, Andrews JR, et al. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 2010;181:80-86.
• 24. Sun Z, Zhang J, Song H, et al. Concomitant increases in spectrum and level of drug resistance in Mycobacterium tuberculosis isolates. Int J Tuberc Lung Dis 2010;14:1436- 1441.
• 25. Crofton J, Chaulet P, Maher D. Guidelines for the management of drug-resistant tuberculosis. Geneva, Switzerland: World Health Organization 1997;1-40.